France Drug Delivery Devices Market

France Drug Delivery Devices Market Insights Forecasts to 2035

• The France Drug Delivery Devices Market Size Was Estimated at USD 17,850 Million in 2024.
• The France Drug Delivery Devices Market Size is Expected to Grow at a CAGR of Around 7.43% from 2025 to 2035.
• The France Drug Delivery Devices Market Size is Expected to Reach USD 39,259.1 Million by 2035.

According to a Research Report Published by Decisions Advisors & Consulting, The France Drug Delivery Devices Market Size is projected to Reach USD 39259.1 Million by 2035, Growing at a CAGR of 7.43% from 2025 to 2035. The drug delivery devices market in France is experiencing mild growth, driven by technological advancements, regulatory changes, and the increasing prevalence of chronic diseases, which are fueling demand for more effective and patient-friendly treatment options.

Market Overview

The France drug delivery devices market encompasses medical devices and technologies used for drug administration within France. This market includes various technologies and products, such as injectable devices, inhalation devices, infusion pumps, and transdermal patches, utilized across diverse therapeutic areas like diabetes, oncology, cardiovascular diseases, and respiratory conditions. Key drivers for this market include the rise in chronic diseases, the demand for convenient and self-administration methods like smart inhalers and auto-injectors, and advancements in connected and smart device technology.

The future of drug delivery systems in France looks promising due to ongoing technological improvements aimed at increasing accuracy, comfort, and efficiency. The market is expected to experience significant changes driven by innovations such as needle-free injections, smart inhalers, insulin pumps with built-in sensors, smart medication delivery systems with digital health monitoring, and the rise of biologics. The integration of AI and digital health technologies has improved patient experience and adherence, driving market growth.

The French drug delivery devices market is focused on smart, connected devices, minimally invasive self-administration, and specialized systems for biologics and targeted therapies. France is experiencing a strong shift toward homecare settings and self-administration, a trend accelerated by the COVID-19 pandemic and patient preference for minimally invasive methods. This increases demand for user-friendly, portable devices.

Report Coverage

This research report categorizes the market for the France drug delivery devices market based on various segments and regions, and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the France drug delivery devices market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the France drug delivery devices market.

Driving Factors

The main drivers of the France drug delivery devices market are the increasing prevalence of chronic diseases, a growing preference for patient-friendly and self-administration methods, and technological advancements. Government initiatives like early reimbursement pathways for digital devices are shortening the time to market and boosting the demand for connected devices like smart inhalers and auto-injectors that improve patient adherence. and a robust healthcare system, as well as innovations in connected devices.

Restraining Factors

Restraining factors for the France drug delivery devices market include strict regulatory hurdles and high costs associated with development, manufacturing, and patient adoption. Other challenges include technical complexities in device design, the need for high patient adherence, safety risks such as needlestick injuries, and potential issues with compatibility and interoperability.

Market Segmentation

The France drug delivery devices market share is classified into product type, distribution channel, and end user.

• The injectable drug delivery segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. 

The France drug delivery device market is segmented by product type into oral drug delivery, injectable drug delivery, topical drug delivery, ophthalmic drug delivery, nasal drug delivery, transmucosal drug delivery, implantable drug delivery, and others. Among these, the injectable drug delivery segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. The segment dominates France drug delivery devices market because it is crucial for managing chronic illnesses, offers advantages like high bioavailability and precision, and is seeing increasing patient preference for user-friendly devices like prefilled syringes and autoinjectors. The growing prevalence of chronic conditions such as diabetes and cancer in France fuels the demand for the injectable drug delivery segment. 

• The hospital pharmacies held the largest share in 2024 and are anticipated to grow at a significant CAGR during the forecast period.

The France drug delivery devices market is segmented by distribution channel into direct tenders, hospital pharmacies, pharmacy stores, and others. Among these, the hospital pharmacy held the largest share in 2024 and is expected to grow at a significant CAGR during the forecast period. The hospital pharmacy segment dominates the drug delivery devices market in France due to its central role in managing inpatient treatments, dispensing challenging therapies like biologics, and its control over a large portion of the healthcare supply chain. Controlling the distribution of many medications is the responsibility of hospital pharmacy, which creates a direct need for a diverse range of delivery systems, particularly for inpatients.

• The hospital segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period.  

The France drug delivery devices market is segmented by end user into hospitals, home healthcare, clinics, community healthcare, and others. Among these, the hospital segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period. The hospital segment dominates the drug delivery devices market in France due to hospitals' role as centralized care providers with advanced infrastructure, the need for precise delivery of complex therapies like intravenous injections, and the increasing prevalence of chronic diseases and the need for management in a hospital setting. Hospitals are experiencing increased demand for these devices due to the increase in the geriatric population and high volume of acute and chronic patients.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the France drug delivery devices market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Becton, Dickinson and Company
• Sanofi
• F. Hoffmann-La Roche AG
• Novo Nordisk
• Johnson & Johnson
• Medtronic
• Lemer Pax
• Gerresheimer AG
• F. Hoffmann-La Roche
• Schneider Electric
• Baxter International
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

In July 2025, Medtronic plc, a global leader in medical technology, announced the CE Mark in Europe to expand indications of the MiniMed 780G system for use by individuals aged 2 years and older, during pregnancy, as well as for type 2 insulin-requiring diabetes.

In January 2024, Lemer Pax, a global leader in radiation protection innovation, and ICU Medical, a medical device company specializing in infusion systems, infusion consumables, and intensive care products, signed a partnership to distribute the Plum 360 pump for the French Nuclear Medicine market.

Market Segment

This study forecasts revenue at the France, regional, and country levels from 2020 to 2035. Decisions Advisors has segmented the France Drug Delivery Devices Market based on the below-mentioned segments:

France Drug Delivery Devices Market, By Product Type

• Oral Drug Delivery
• Injectable Drug Delivery
• Topical Drug Delivery
• Ophthalmic Drug Delivery
• Nasal Drug Delivery
• Transmucosal Drug Delivery
• Implantable Drug Delivery
• Others

France Drug Delivery Devices Market, By Distribution Channel

• Direct Tenders
• Hospital Pharmacies
• Pharmacy Stores
• Others

France Drug Delivery Devices Market, By End User

• Hospitals
• Home Healthcare
• Clinics
• Community Healthcare
• Others